REG - Belluscura PLC - Board Appointment

BelluscuraAnnouncement

12/09/2025 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250912:nRSL2098Za&default-theme=true

RNS Number : 2098Z  Belluscura PLC  12 September 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER
THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF
ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura plc

("Belluscura" or the "Company" or "Group")

 

Board Appointment

 

Belluscura has appointed Guy Peters as non executive director

 

LONDON, U.K. and PLANO, TX, U.S. (12 September 2025). Belluscura plc
(AIM:BELL), a leading medical device developer focused on lightweight and
portable oxygen enrichment technology, announces that Guy Peters has joined
the Board as a non-executive director with immediate effect.

Guy is a qualified solicitor who moved into merchant and investment banking
early in his career. He has over 30 years' experience working with small to
medium sized businesses across a broad variety of sectors as a board member or
as an external corporate financier, stockbroking advisor, solicitor or
consultant. His expertise encompasses operational, business development, legal
and accounting matters as well as IPOs, fundraisings, acquisitions, mergers
and disposals.

In recent months Guy has been assisting, Omaha Value, Inc. ("Omaha"), a
private US-based merchant banking and investment group which had made a
funding proposal to the Company, as set out in the Company's notification of
30 June 2025,

The Company announced on 11 August 2025 that it had terminated its agreement
with Omaha, and that it had proceeded to sign a non-binding letter of intent
with another US company for that company to acquire certain assets and
liabilities of Belluscura LLC, the Company's wholly-owned US subsidiary. The
potential acquiror was granted an exclusivity period to complete its due
diligence. This period of exclusivity has now expired, and no definitive
agreement has been signed.

With the expiry of the aforementioned exclusivity period, the Company has been
approached once more by Omaha to consider a revised funding proposal from
Omaha and a connected company called AI Ventures, Inc, (together the "Omaha
Investor Group") with a proposal to refinance the Company. The Company, with
Guy's assistance, is continuing to evaluate a range of options to
substantially strengthen Belluscura's capital position, supporting both the
Company's short-term cash requirements and its significant medium-term growth
prospects.  Any agreement with Omaha will involve Guy receiving a share of
the fees and other rewards due to Omaha, details of which will be notified as
part of any requisite shareholders' approval process and subject to any
necessary consents to be obtained at the time.

While the Board can confirm that discussions regarding the Fundraising are
proceeding as set out above, there can be no certainty that the Fundraising
will be completed.  If the Fundraising does not proceed as set out above in
the next few days the Company will be unable to meet its immediate cash
requirements.

The ongoing funding discussions means that the Company is still not yet able
to finalise the 2024 Annual Report and Accounts and as a result trading in the
Company's shares on AIM remains suspended.

AIM Rules Schedule 2(g) disclosures

Pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for
Companies, Guy Richard Peters is, or has during the last five years, been a
director or partner of the following companies and partnerships:

 Current Directorships or Partnerships  Previous Directorships or Partnerships
 Triple O Corporate Services Limited    Hydrogen Utopia International PLC

 Accounting Value Solutions Limited     HU2021 International UK Limited

 D.E.S Properties Limited

 

Guy Peters was appointed a director and CEO of Hume Capital Securities PLC on
23 June 2014 and resigned on 16 March 2015. Guy resigned following the
appointment of a special administrator. Guy agreed to become a director and
CEO on the basis that a refinancing seemed very likely at the time.
Ultimately, the Financial Conduct Authority ("FCA") decided that a refinancing
was unlikely to work and suggested to the then Chairman that the Board should
put Hume Capital Securities PLC into special administration to protect
clients' assets. Hume Capital Securities was put into special administration
on 16 March 2015. Whilst the Special Administration is yet to complete, the
loss to creditors is not expected to be more than £1.75m.

Hume Capital Securities PLC was named XCap Securities PLC between 27 July 2010
- 5 February 2014. On 31 May 2013, the FCA imposed a financial penalty of
£120,900 on XCap Securities PLC for breaches of certain rules regarding
protection of client money and client assets. The actual breaches occurred
between 29 June 2010 and 31 August 2011. Both the breaches and the imposition
of the fine occurred before Guy Peters was employed by XCap Securities PLC and
more than a year before he became a director and CEO of Hume Capital
Securities PLC.

 

Guy holds no shares in Belluscura. There are no other disclosures under AIM
Rules Schedule 2(g).

 

 

For further information please contact:

 

 

 Belluscura plc                                             Tel: +44 (0)20 3128 8100
 Paul Tuson, Chairman
 Robert Rauker, Chief Executive Officer

 SPARK Advisory Partners Limited - Nominated Adviser        Tel: +44 (0)20 3368 3550
 Neil Baldwin / Dillon Wall

 Dowgate Capital Limited - Joint Broker                     Tel: +44 (0)20 3903 7715
 Russell Cook / Daniel Ingram

 Allenby Capital Limited - Joint Broker                     Tel: +44 (0)20 3328 5656
 Guy McDougall / Amrit Nahal (Sales and Corporate Broking)
 Jeremy Porter / Lauren Wright (Corporate Finance)

 MHP - Financial PR & Investor Relations                    Tel: +44 (0)20 3128 8100
 Katie Hunt / Matthew Taylor                                email: Belluscura@mhpgroup.com

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUUVVRVUUKAAR